Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

And the winner is?

This article was originally published in The Tan Sheet

Executive Summary

Cogene Biotech Ventures CEO Thomas Caskey, MD, and Stanford University School of Medicine cardiology professor Paul Yock, MD, are now being considered as FDA Commissioner candidates by Bush Administration. Strong ties to academia (Caskey taught at Baylor College of Medicine for 25 years) probably is major reason for recent consideration; Senate Health Committee Chairman Edward Kennedy (D-Mass.) discouraged Administration from nominating candidates with ties to industry in a July 13 letter (1"The Tan Sheet" July 23, p. 17)

You may also be interested in...



Sen. Kennedy Warns Against Picking FDA Commissioner From Industry

The key attributes for the next FDA commissioner - from Sen. Edward Kennedy's point of view - appear to lend support to the candidacy of Harvard Medical School dermatology lecturer Lynn Drake, MD.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel